BACKGROUND: T-cell responses have been described in seronegative patients who test negative for hepatitis C virus (HCV) RNA despite frequent HCV exposure. However, the cross-sectional design of those studies did not clarify whether T cells were indeed induced by low-level HCV exposure without seroconversion or whether they resulted from regular acute infection with subsequent antibody loss. METHODS: Over a 10-year period, our longitudinal study recruited 72 healthcare workers with documented HCV exposure. We studied viremia and antibody and T-cell responses longitudinally for 6 months. RESULTS: All healthcare workers remained negative for HCV RNA and antibodies. However, 48% developed proliferative T-cell response and 42% developed responses in interferon-gamma enzyme-linked immunosorbent spot assays, with 29 healthy HCV-unexposed controls used to define assay cutoffs. The response prevalence was associated with the transmission risk score. T-cell responses peaked at week 4 and returned to baseline by week 12 after exposure. They predominantly targeted nonstructural HCV proteins, which are not part of the HCV particle and thus must have been synthesized in infected cells. CONCLUSIONS: Subclinical transmission of HCV occurs frequently, resulting in infection and synthesis of nonstructural proteins despite undetectable systemic viremia. T-cell responses are more sensitive indicators of this low-level HCV exposure than antibodies.
BACKGROUND: T-cell responses have been described in seronegative patients who test negative for hepatitis C virus (HCV) RNA despite frequent HCV exposure. However, the cross-sectional design of those studies did not clarify whether T cells were indeed induced by low-level HCV exposure without seroconversion or whether they resulted from regular acute infection with subsequent antibody loss. METHODS: Over a 10-year period, our longitudinal study recruited 72 healthcare workers with documented HCV exposure. We studied viremia and antibody and T-cell responses longitudinally for 6 months. RESULTS: All healthcare workers remained negative for HCV RNA and antibodies. However, 48% developed proliferative T-cell response and 42% developed responses in interferon-gamma enzyme-linked immunosorbent spot assays, with 29 healthy HCV-unexposed controls used to define assay cutoffs. The response prevalence was associated with the transmission risk score. T-cell responses peaked at week 4 and returned to baseline by week 12 after exposure. They predominantly targeted nonstructural HCV proteins, which are not part of the HCV particle and thus must have been synthesized in infected cells. CONCLUSIONS: Subclinical transmission of HCV occurs frequently, resulting in infection and synthesis of nonstructural proteins despite undetectable systemic viremia. T-cell responses are more sensitive indicators of this low-level HCV exposure than antibodies.
Entities:
Keywords:
T cell; antibody; exposure; healthcare worker; hepatitis; needlestick
Authors: A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann Journal: Nat Med Date: 2000-05 Impact factor: 53.440
Authors: Nattawan Promadej; Caroline Costello; Mary M Wernett; Prasad S Kulkarni; Valerie A Robison; Kenrad E Nelson; Thomas W Hodge; Vinai Suriyanon; Ann Duerr; Janet M McNicholl Journal: J Infect Dis Date: 2003-03-19 Impact factor: 5.226
Authors: Tram N Q Pham; Sonya A MacParland; Patricia M Mulrooney; Helen Cooksley; Nikolai V Naoumov; Tomasz I Michalak Journal: J Virol Date: 2004-06 Impact factor: 5.103
Authors: Arash Grakoui; Naglaa H Shoukry; David J Woollard; Jin-Hwan Han; Holly L Hanson; John Ghrayeb; Krishna K Murthy; Charles M Rice; Christopher M Walker Journal: Science Date: 2003-10-24 Impact factor: 47.728
Authors: Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker Journal: J Exp Med Date: 2003-06-16 Impact factor: 14.307
Authors: Peter J Kuebler; Megha L Mehrotra; J Jeff McConnell; Sara J Holditch; Brian I Shaw; Leandro F Tarosso; Kaitlyn S Leadabrand; Jeffrey M Milush; Vanessa A York; Rui André Saraiva Raposo; Rex G Cheng; Emily M Eriksson; Vanessa McMahan; David V Glidden; Stephen Shiboski; Robert M Grant; Douglas F Nixon; Esper G Kallás Journal: Proc Natl Acad Sci U S A Date: 2015-06-22 Impact factor: 11.205
Authors: Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme Journal: Clin Vaccine Immunol Date: 2014-01-15
Authors: Chalermrat Bunchorntavakul; Lisa M Jones; Masahiro Kikuchi; Mary E Valiga; David E Kaplan; Frederick A Nunes; Ayse Aytaman; K Rajender Reddy; Kyong-Mi Chang Journal: J Clin Gastroenterol Date: 2015-04 Impact factor: 3.062